Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.51 |
| ▸ | FNTB | P49356 | 2/20 | 0.51 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PTAFR | P25105 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12777874 | 0.87 | FNTA (0.50) | FNTAFNTBSETD7OPRD1OPRK1 | |
| SCHEMBL12751036 | 0.85 | FNTA (0.49) | FNTAFNTBSETD7OPRD1SMN1; SMN2 | |
| SCHEMBL14262776 | 0.83 | SETD7 (0.61) | FNTAFNTBSETD7OPRD1OPRK1 | |
| SCHEMBL1473049 | 0.83 | FNTA (0.46) | FNTAFNTB | |
| SCHEMBL12751048 | 0.80 | CYP2C9 (0.50) | FNTAFNTBSETD7OPRD1HTT | |
| SCHEMBL14252950 | 0.79 | SETD7 (0.43) | FNTAFNTBSETD7OPRD1OPRK1 | |
| SCHEMBL31350902 | 0.76 | FNTA (0.49) | FNTAFNTBSETD7HPGDHTT | |
| SCHEMBL12751033 | 0.75 | GAA (0.49) | FNTAFNTBSMN1; SMN2PTAFR | |
| SCHEMBL12751838 | 0.75 | FNTA (0.48) | FNTAFNTBSETD7OPRD1HPGD | |
| SCHEMBL12751042 | 0.74 | SETD7 (0.46) | FNTAFNTBSETD7OPRD1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915283-B2 | e.g. 1-[4-(1-Phenyl-1-(pyrazinyl)-methylene)-piperidin-1-yl]-2-(4-methoxy-7-pyrazinyl-6-azaindol-3-yl)-ethane-1,2-dione; viricides for prophylaxis of lympadenopathy associated virus; synergystic mixtures with immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-7902204-B2 | 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-07 | — | — | US | disclosed |
| US-20080125439-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-29 | — | — | US | disclosed |
| US-7348337-B2 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125439-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, EIF2AK2 | FNTA 2786/4885FNTB 1834/4885SETD7 2513/4885 |
| US-20080188481-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES | IDO1, IDO2, INMT | FNTA 2583/4885FNTB 3319/4885SETD7 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.